The USFDA has approved a 30-minute onset of action for Focalin XR (dexmethylphenidate HCl) ER capsules for the treatment of Attention Deficit/Hyperactivity Disorder, bringing potential benefits for young patients and their families during the important morning period when they are preparing for school.
The details can be read here.
No comments:
Post a Comment